Mirdametinib blocks MEK phosphorylation and downstream ERK signaling, resulting in reduced tumor growth and symptom burden in NF1 patients.99 The drug is orally bioavailable and is suitable for use in both adult and pediatric populations. The gene discussed is MAP2K7; the disease is neoplasm.